Sensus Healthcare to Host Fourth Quarter 2020 Financial Results and Business Update
Conference Call on February 25, 2021
BOCA RATON, Fla. (February 18, 2021) – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device
company specializing in highly effective, non-invasive treatments for both oncological and nononcological conditions, announces that management will hold a conference call on Thursday, February
25, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter of 2020. In
addition, management will provide a business update and a discussion on recent and upcoming
To access the conference call, the dial-in numbers are 888-390-3967 (U.S. and Canada Toll Free), 862-298-
0702 (International). Please direct the operator to be connected to the Sensus Healthcare conference call.
The call will be webcast live and can be accessed at the following link, which also may be found in the
Investor Relations section of the Company’s website at www.sensushealthcare.com.
Following the conclusion of the conference call, a replay will be available and can be accessed by dialing
888-539-4649 (U.S. and Canada Toll Free), or 754-333-7735 (International). At the system prompt, dial
the replay code – 155222 followed by the # sign. Playback will automatically begin. An archived webcast
of the call will also be available in the Investor Relations section of the Company’s website for a period of
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive,
minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The
Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted Directional
Anisotropic Radiation Therapy (ART) and Brachytherapy utilizing our proprietary, state-of-the-art 3D
Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast
and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial
radiation therapy (SRT), which is the culmination of more than a decade of research and development, to
treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™
systems. With its portfolio of innovative medical device products, Sensus provides revolutionary
treatment options to enhance the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
LHA Investor Relations
Kim Sutton Golodetz